Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 13 years, with Dec 2024 value amounting to $46.2 million.

  • Northwest Biotherapeutics' Other Non-Current Liabilities rose 87.02% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 87.02%. This contributed to the annual value of $46.2 million for FY2024, which is 97.40% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Other Non-Current Liabilities stood at $46.2 million for FY2024, which was up 97.40% from $23.4 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Other Non-Current Liabilities registered a high of $365.8 million during FY2020, and its lowest value of $23.4 million during FY2023.
  • In the last 3 years, Northwest Biotherapeutics' Other Non-Current Liabilities had a median value of $46.2 million in 2024 and averaged $53.4 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Other Non-Current Liabilities spiked by 1,231.27% in 2020, and later plummeted by 74.22% in 2023.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Other Non-Current Liabilities stood at $365.8 million in 2020, then tumbled by 68.28% to $116.0 million in 2021, then decreased by 21.80% to $90.7 million in 2022, then plummeted by 74.22% to $23.4 million in 2023, then skyrocketed by 97.40% to $46.2 million in 2024.